S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.03%) $0.927
USD/NOK
(-0.06%) $10.83
USD/GBP
(-0.09%) $0.792
USD/RUB
(-0.21%) $92.38

Realtime updates for Amgen Inc [AMG.DE]

Exchange: XETRA Sector: Biotechnology Industry: Drug Manufacturers—General
Last Updated28 Mar 2024 @ 12:35

0.00% 264.40

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 12:35):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...

Stats
Today's Volume 470.00
Average Volume 574.00
Market Cap 141.70B
EPS €0 ( 2024-02-05 )
Next earnings date ( €0 ) 2024-04-24
Last Dividend €2.13 ( 2023-08-17 )
Next Dividend €0 ( N/A )
P/E 22.95
ATR14 €0.737 (0.28%)

Amgen Inc Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amgen Inc Financials

Annual 2023
Revenue: €28.19B
Gross Profit: €19.74B (70.02 %)
EPS: €12.56
Q4 2023
Revenue: €8.20B
Gross Profit: €5.08B (62.03 %)
EPS: €1.300
Q3 2023
Revenue: €6.90B
Gross Profit: €5.10B (73.84 %)
EPS: €3.23
Q2 2023
Revenue: €6.99B
Gross Profit: €5.17B (74.05 %)
EPS: €2.58

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€1.940
(N/A)
€1.940
(N/A)
€2.13
(N/A)
€2.13
(N/A)
€2.13
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Amgen Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.54 - Stable (9.18%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.280 2011-08-16
Last Dividend €2.13 2023-08-17
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 49 --
Total Paid Out €56.75 --
Avg. Dividend % Per Year 0.00% --
Score 4.22 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.54
Div. Directional Score 7.42 --
Next Divdend (Est)
(2024-04-01)
€2.17 Estimate 29.69 %
Dividend Stability
0.79 Good
Dividend Score
4.22
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WAC.DE Ex Dividend Junior 2023-05-29 Annually 0 0.00%
GXI.DE Ex Dividend Junior 2023-06-08 Annually 0 0.00%
PHM7.DE Ex Dividend Knight 2023-09-14 Quarterly 0 0.00%
CAR.DE Ex Dividend Knight 2023-06-06 Annually 0 0.00%
IC1B.F Ex Dividend Junior 2023-08-31 Annually 0 0.00%
SGE.DE Ex Dividend Junior 2023-05-30 Annually 0 0.00%
DEQ.DE Ex Dividend Junior 2023-08-30 Annually 0 0.00%
LAR.DE Ex Dividend Knight 2023-09-12 Quarterly 0 0.00%
AB9.DE Ex Dividend Junior 2023-04-28 Sporadic 0 0.00%
TMLF.F Ex Dividend Junior 2023-04-12 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2381.5005.237.85[0 - 0.5]
returnOnAssetsTTM0.06911.2007.709.23[0 - 0.3]
returnOnEquityTTM1.0331.50010.0010.00[0.1 - 1]
payoutRatioTTM0.678-1.0003.22-3.22[0 - 1]
currentRatioTTM1.6490.8006.755.40[1 - 3]
quickRatioTTM1.0270.8008.676.93[0.8 - 2.5]
cashRatioTTM0.5951.5007.8110.00[0.2 - 2]
debtRatioTTM0.665-1.50010.00-10.00[0 - 0.6]
interestCoverageTTM3.151.0009.949.94[3 - 30]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
freeCashFlowPerShareTTM13.762.003.126.24[0 - 20]
debtEquityRatioTTM10.37-1.50010.00-10.00[0 - 2.5]
grossProfitMarginTTM0.7001.0001.6631.663[0.2 - 0.8]
operatingProfitMarginTTM0.3211.0005.575.57[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1311.000-0.383-0.383[0.2 - 2]
assetTurnoverTTM0.2900.800-1.399-1.119[0.5 - 2]
Total Score10.30

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM22.691.0007.810[1 - 100]
returnOnEquityTTM1.0332.503.3410.00[0.1 - 1.5]
freeCashFlowPerShareTTM13.762.005.416.24[0 - 30]
dividendYielPercentageTTM3.031.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM15.832.004.729.44[0 - 30]
payoutRatioTTM0.6781.5003.22-3.22[0 - 1]
pegRatioTTM-5.841.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3001.0004.990[0.1 - 0.5]
Total Score4.54

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators